October 20, Karin Agerman presents at ATMP Sweden’s webinar “Manufacturing of Gene Therapy Products in Sweden”

Oct 14, 2020

CombiGenes Chief Research and Development Officer Karin Agerman presents at ATMP Sweden’s webinar “Manufacturing of Gene Therapy Products in Sweden”
On October 20, 2020, Karin Agerman gives her views on the production of gene therapies in Sweden under the heading A small company’s perspective on manufacture of in vivo gene therapy in Sweden for clinical trial.

https://atmpsweden.se/events/manufacturing-of-gene-therapy-products-a-swedish-perspective/

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

Linked In     Twitter      Facebook